Search

Your search keyword '"Polley, Mei-Yin C"' showing total 50 results
Start Over Author "Polley, Mei-Yin C" Publication Year Range Last 50 years
50 results on '"Polley, Mei-Yin C"'

1. Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses

Author

Chen, William C, Choudhury, Abrar, Youngblood, Mark W, Polley, Mei-Yin C, Lucas, Calixto-Hope G, Mirchia, Kanish, Maas, Sybren LN, Suwala, Abigail K, Won, Minhee, Bayley, James C, Harmanci, Akdes S, Harmanci, Arif O, Klisch, Tiemo J, Nguyen, Minh P, Vasudevan, Harish N, McCortney, Kathleen, Yu, Theresa J, Bhave, Varun, Lam, Tai-Chung, Pu, Jenny Kan-Suen, Li, Lai-Fung, Leung, Gilberto Ka-Kit, Chan, Jason W, Perlow, Haley K, Palmer, Joshua D, Haberler, Christine, Berghoff, Anna S, Preusser, Matthias, Nicolaides, Theodore P, Mawrin, Christian, Agnihotri, Sameer, Resnick, Adam, Rood, Brian R, Chew, Jessica, Young, Jacob S, Boreta, Lauren, Braunstein, Steve E, Schulte, Jessica, Butowski, Nicholas, Santagata, Sandro, Spetzler, David, Bush, Nancy Ann Oberheim, Villanueva-Meyer, Javier E, Chandler, James P, Solomon, David A, Rogers, C Leland, Pugh, Stephanie L, Mehta, Minesh P, Sneed, Penny K, Berger, Mitchel S, Horbinski, Craig M, McDermott, Michael W, Perry, Arie, Bi, Wenya Linda, Patel, Akash J, Sahm, Felix, Magill, Stephen T, and Raleigh, David R

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Brain Disorders, Brain Cancer, Rare Diseases, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Humans, Biomarkers, Gene Expression Profiling, Meningeal Neoplasms, Meningioma, Neoplasm Recurrence, Local, Prospective Studies, Medical and Health Sciences, Immunology, Biomedical and clinical sciences, Health sciences
Abstract

Surgery is the mainstay of treatment for meningioma, the most common primary intracranial tumor, but improvements in meningioma risk stratification are needed and indications for postoperative radiotherapy are controversial. Here we develop a targeted gene expression biomarker that predicts meningioma outcomes and radiotherapy responses. Using a discovery cohort of 173 meningiomas, we developed a 34-gene expression risk score and performed clinical and analytical validation of this biomarker on independent meningiomas from 12 institutions across 3 continents (N = 1,856), including 103 meningiomas from a prospective clinical trial. The gene expression biomarker improved discrimination of outcomes compared with all other systems tested (N = 9) in the clinical validation cohort for local recurrence (5-year area under the curve (AUC) 0.81) and overall survival (5-year AUC 0.80). The increase in AUC compared with the standard of care, World Health Organization 2021 grade, was 0.11 for local recurrence (95% confidence interval 0.07 to 0.17, P

Published
2023

6. A clinical calculator to predict disease outcomes in women with triple-negative breast cancer

Author

Polley, Mei-Yin C., Leon-Ferre, Roberto A., Leung, Samuel, Cheng, Angela, Gao, Dongxia, Sinnwell, Jason, Liu, Heshan, Hillman, David W., Eyman-Casey, Abraham, Gilbert, Judith A., Negron, Vivian, Boughey, Judy C., Liu, Minetta C., Ingle, James N., Kalari, Krishna, Couch, Fergus, Carter, Jodi M., Visscher, Daniel W., Nielsen, Torsten O., and Goetz, Matthew P.

Published
2021
Full Text
View/download PDF

7. Table S2 from Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1–positive Triple-negative Breast Cancer

Author

Carter, Jodi M., primary, Polley, Mei-Yin C., primary, Leon-Ferre, Roberto A., primary, Sinnwell, Jason, primary, Thompson, Kevin J., primary, Wang, Xue, primary, Ma, Yaohua, primary, Zahrieh, David, primary, Kachergus, Jennifer M., primary, Solanki, Malvika, primary, Boughey, Judy C., primary, Liu, Minetta C., primary, Ingle, James N., primary, Kalari, Krishna R., primary, Couch, Fergus J., primary, Thompson, E. Aubrey, primary, and Goetz, Matthew P., primary

Published
2023
Full Text
View/download PDF

8. Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration

Author

McShane, Lisa M, Cavenagh, Margaret M, Lively, Tracy G, Eberhard, David A, Bigbee, William L, Williams, P Mickey, Mesirov, Jill P, Polley, Mei-Yin C, Kim, Kelly Y, Tricoli, James V, Taylor, Jeremy MG, Shuman, Deborah J, Simon, Richard M, Doroshow, James H, and Conley, Barbara A

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Cancer, Clinical Research, Generic health relevance, Good Health and Well Being, Biomedical Research, Clinical Trials as Topic, Genomics, Guidelines as Topic, High-Throughput Screening Assays, Humans, Precision Medicine, Reproducibility of Results, Research Design, Analytical validation, Biomarker, Diagnostic test, Genomic classifier, Model validation, Molecular profile, Omics, Personalized medicine, Treatment selection, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

High-throughput 'omics' technologies that generate molecular profiles for biospecimens have been extensively used in preclinical studies to reveal molecular subtypes and elucidate the biological mechanisms of disease, and in retrospective studies on clinical specimens to develop mathematical models to predict clinical endpoints. Nevertheless, the translation of these technologies into clinical tests that are useful for guiding management decisions for patients has been relatively slow. It can be difficult to determine when the body of evidence for an omics-based test is sufficiently comprehensive and reliable to support claims that it is ready for clinical use, or even that it is ready for definitive evaluation in a clinical trial in which it may be used to direct patient therapy. Reasons for this difficulty include the exploratory and retrospective nature of many of these studies, the complexity of these assays and their application to clinical specimens, and the many potential pitfalls inherent in the development of mathematical predictor models from the very high-dimensional data generated by these omics technologies. Here we present a checklist of criteria to consider when evaluating the body of evidence supporting the clinical use of a predictor to guide patient therapy. Included are issues pertaining to specimen and assay requirements, the soundness of the process for developing predictor models, expectations regarding clinical study design and conduct, and attention to regulatory, ethical, and legal issues. The proposed checklist should serve as a useful guide to investigators preparing proposals for studies involving the use of omics-based tests. The US National Cancer Institute plans to refer to these guidelines for review of proposals for studies involving omics tests, and it is hoped that other sponsors will adopt the checklist as well.

Published
2013

9. Criteria for the use of omics-based predictors in clinical trials

Author

McShane, Lisa M, Cavenagh, Margaret M, Lively, Tracy G, Eberhard, David A, Bigbee, William L, Williams, P Mickey, Mesirov, Jill P, Polley, Mei-Yin C, Kim, Kelly Y, Tricoli, James V, Taylor, Jeremy MG, Shuman, Deborah J, Simon, Richard M, Doroshow, James H, and Conley, Barbara A

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Trials and Supportive Activities, Clinical Research, Cancer, Good Health and Well Being, Checklist, Clinical Trials as Topic, Evaluation Studies as Topic, Genomics, Humans, Models, Biological, National Cancer Institute (U.S.), Precision Medicine, Research Design, Specimen Handling, United States, General Science & Technology
Abstract

The US National Cancer Institute (NCI), in collaboration with scientists representing multiple areas of expertise relevant to 'omics'-based test development, has developed a checklist of criteria that can be used to determine the readiness of omics-based tests for guiding patient care in clinical trials. The checklist criteria cover issues relating to specimens, assays, mathematical modelling, clinical trial design, and ethical, legal and regulatory aspects. Funding bodies and journals are encouraged to consider the checklist, which they may find useful for assessing study quality and evidence strength. The checklist will be used to evaluate proposals for NCI-sponsored clinical trials in which omics tests will be used to guide therapy.

Published
2013

10. Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients

Author

Norton, Nadine, Youssef, Bahaaeldin, Hillman, David W., Nassar, Aziza, Geiger, Xochiquetzal J., Necela, Brian M., Liu, Heshan, Ruddy, Kathryn J., Polley, Mei-Yin C., Ingle, James N., Couch, Fergus J., Perez, Edith A., Liu, Minetta C., Carter, Jodi M., Leon-Ferre, Roberto A., Boughey, Judy C., Somers, Elizabeth B., Kalari, Krishna R., Visscher, Daniel W., Goetz, Matthew P., and Knutson, Keith L.

Published
2020
Full Text
View/download PDF

12. Supplementary Table 1 from Oncogenic BRAF Mutation with CDKN2A Inactivation Is Characteristic of a Subset of Pediatric Malignant Astrocytomas

Author

Schiffman, Joshua D., primary, Hodgson, J. Graeme, primary, VandenBerg, Scott R., primary, Flaherty, Patrick, primary, Polley, Mei-Yin C., primary, Yu, Mamie, primary, Fisher, Paul G., primary, Rowitch, David H., primary, Ford, James M., primary, Berger, Mitchel S., primary, Ji, Hanlee, primary, Gutmann, David H., primary, and James, C. David, primary

Published
2023
Full Text
View/download PDF

13. Data from Oncogenic BRAF Mutation with CDKN2A Inactivation Is Characteristic of a Subset of Pediatric Malignant Astrocytomas

Author

Schiffman, Joshua D., primary, Hodgson, J. Graeme, primary, VandenBerg, Scott R., primary, Flaherty, Patrick, primary, Polley, Mei-Yin C., primary, Yu, Mamie, primary, Fisher, Paul G., primary, Rowitch, David H., primary, Ford, James M., primary, Berger, Mitchel S., primary, Ji, Hanlee, primary, Gutmann, David H., primary, and James, C. David, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure 1 from Oncogenic BRAF Mutation with CDKN2A Inactivation Is Characteristic of a Subset of Pediatric Malignant Astrocytomas

Author

Schiffman, Joshua D., primary, Hodgson, J. Graeme, primary, VandenBerg, Scott R., primary, Flaherty, Patrick, primary, Polley, Mei-Yin C., primary, Yu, Mamie, primary, Fisher, Paul G., primary, Rowitch, David H., primary, Ford, James M., primary, Berger, Mitchel S., primary, Ji, Hanlee, primary, Gutmann, David H., primary, and James, C. David, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Table 2 from Oncogenic BRAF Mutation with CDKN2A Inactivation Is Characteristic of a Subset of Pediatric Malignant Astrocytomas

Author

Schiffman, Joshua D., primary, Hodgson, J. Graeme, primary, VandenBerg, Scott R., primary, Flaherty, Patrick, primary, Polley, Mei-Yin C., primary, Yu, Mamie, primary, Fisher, Paul G., primary, Rowitch, David H., primary, Ford, James M., primary, Berger, Mitchel S., primary, Ji, Hanlee, primary, Gutmann, David H., primary, and James, C. David, primary

Published
2023
Full Text
View/download PDF

16. Reply to B. Zhao et al

Author

Polley, Mei-Yin C., primary, Gorlia, Thierry, additional, Lassman, Andy B., additional, and van den Bent, Martin J., additional

Published
2023
Full Text
View/download PDF

17. An international study to increase concordance in Ki67 scoring

Author

Polley, Mei-Yin C, Leung, Samuel C Y, Gao, Dongxia, Mastropasqua, Mauro G, Zabaglo, Lila A, Bartlett, John M S, McShane, Lisa M, Enos, Rebecca A, Badve, Sunil S, Bane, Anita L, Borgquist, Signe, Fineberg, Susan, Lin, Ming-Gang, Gown, Allen M, Grabau, Dorthe, Gutierrez, Carolina, Hugh, Judith C, Moriya, Takuya, Ohi, Yasuyo, Osborne, C Kent, Penault-Llorca, Frédérique M, Piper, Tammy, Porter, Peggy L, Sakatani, Takashi, Salgado, Roberto, Starczynski, Jane, Lænkholm, Anne-Vibeke, Viale, Giuseppe, Dowsett, Mitch, Hayes, Daniel F, and Nielsen, Torsten O

Published
2015
Full Text
View/download PDF

18. Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors

Author

Lassman, Andrew B., primary, Hoang-Xuan, Khê, additional, Polley, Mei-Yin C., additional, Brandes, Alba A., additional, Cairncross, J. Gregory, additional, Kros, Johan M., additional, Ashby, Lynn S., additional, Taphoorn, Martin J.B., additional, Souhami, Luis, additional, Dinjens, Winand N.M., additional, Laack, Nadia N., additional, Kouwenhoven, Mathilde C.M., additional, Fink, Karen L., additional, French, Pim J., additional, Macdonald, David R., additional, Lacombe, Denis, additional, Won, Minhee, additional, Gorlia, Thierry, additional, Mehta, Minesh P., additional, and van den Bent, Martin J., additional

Published
2022
Full Text
View/download PDF

19. CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer

Author

Shepherd, Jonathan H., primary, Ballman, Karla, additional, Polley, Mei-Yin C., additional, Campbell, Jordan D., additional, Fan, Cheng, additional, Selitsky, Sara, additional, Fernandez-Martinez, Aranzazu, additional, Parker, Joel S., additional, Hoadley, Katherine A., additional, Hu, Zhiyuan, additional, Li, Yan, additional, Soloway, Matthew G., additional, Spears, Patricia A., additional, Singh, Baljit, additional, Tolaney, Sara M., additional, Somlo, George, additional, Port, Elisa R., additional, Ma, Cynthia, additional, Kuzma, Charles, additional, Mamounas, Eleftherios, additional, Golshan, Mehra, additional, Bellon, Jennifer R., additional, Collyar, Deborah, additional, Hahn, Olwen M., additional, Hudis, Clifford A., additional, Winer, Eric P., additional, Partridge, Ann, additional, Hyslop, Terry, additional, Carey, Lisa A., additional, Perou, Charles M., additional, and Sikov, William M., additional

Published
2022
Full Text
View/download PDF

20. Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1–positive Triple-negative Breast Cancer

Author

Carter, Jodi M., primary, Polley, Mei-Yin C., additional, Leon-Ferre, Roberto A., additional, Sinnwell, Jason, additional, Thompson, Kevin J., additional, Wang, Xue, additional, Ma, Yaohua, additional, Zahrieh, David, additional, Kachergus, Jennifer M., additional, Solanki, Malvika, additional, Boughey, Judy C., additional, Liu, Minetta C., additional, Ingle, James N., additional, Kalari, Krishna R., additional, Couch, Fergus J., additional, Thompson, E. Aubrey, additional, and Goetz, Matthew P., additional

Published
2021
Full Text
View/download PDF

22. Two-Stage Adaptive Design for Prognostic Biomarker Signatures With a Survival Endpoint.

Author

Dai, Biyue and Polley, Mei-Yin C.

Subjects
*TRIPLE-negative breast cancer, *SURVIVAL analysis (Biometry), *NULL hypothesis, *STATISTICAL significance
Abstract

Cancer biomarker discoveries typically involve using patient specimens. In practice, there is often strong desire to preserve high quality biospecimens for studies that are most likely to yield useful information. Previously, we proposed a two-stage adaptive design for binary endpoints which terminates the biomarker study in a futility interim if the model performance is unsatisfactory. In this work, we extend the two-stage design framework to accommodate time-to-event endpoints. The first stage of the procedure involves testing whether the measure of discrimination for survival models (C-index) exceeds a prespecified threshold. We describe the computation of cross-validated C-index and evaluation of the statistical significance using resampling techniques. The second stage involves an independent model validation. Our simulation studies show that under the null hypothesis, the proposed design maintains Type I error at the nominal level and has high probabilities of terminating the study early. Under the alternative hypothesis, power of the design is a function of the true event proportion, the sample size, and the targeted improvement in the discriminant measure. We apply the method to design of a prognostic biomarker study in patients with triple-negative breast cancer. Some practical aspects of the proposed method are discussed. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

23. Abstract PS10-02: A good prognosis of endocrine-dependent tumors among residual invasive cancer after anti-HER2 therapy: CALGB 40601 (Alliance) and validation studies

Author

Ahn, Sung Gwe, primary, Fernandez-Martinez, Aranzazu, additional, Polley, Mei-Yin C., additional, Bae, Soong June, additional, Park, Seho, additional, Chic, Núria, additional, Brasó-Maristany, Fara, additional, Conte, Benedetta, additional, Guarneri, Valentina, additional, Dieci, Maria Vittoria, additional, Griguolo, Gaia, additional, Conte, PierFranco, additional, Jeong, Joon, additional, Prat, Aleix, additional, Carey, Lisa A., additional, and Perou, Charles M, additional

Published
2021
Full Text
View/download PDF

25. An International Ki67 Reproducibility Study

Author

Polley, Mei-Yin C., Leung, Samuel C. Y., McShane, Lisa M., Gao, Dongxia, Hugh, Judith C., Mastropasqua, Mauro G., Viale, Giuseppe, Zabaglo, Lila A., Penault-Llorca, Frédérique, Bartlett, John M.S., Gown, Allen M., Symmans, W. Fraser, Piper, Tammy, Mehl, Erika, Enos, Rebecca A., Hayes, Daniel F., Dowsett, Mitch, and Nielsen, Torsten O.

Published
2013
Full Text
View/download PDF

28. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial

Author

Schöder, Heiko, primary, Polley, Mei-Yin C., primary, Knopp, Michael V., primary, Hall, Nathan, primary, Kostakoglu, Lale, primary, Zhang, Jun, primary, Higley, Howard R., primary, Kelloff, Gary, primary, Liu, Heshan, primary, Zelenetz, Andrew D., primary, Cheson, Bruce D., primary, Wagner-Johnston, Nina, primary, Kahl, Brad S., primary, Friedberg, Jonathan W., primary, Hsi, Eric D., primary, Leonard, John P., primary, Schwartz, Lawrence H., primary, Wilson, Wyndham H., primary, and Bartlett, Nancy L., primary

Published
2020
Full Text
View/download PDF

29. Abstract PD1-08: Frequency, characteristics and prognostic factors of PD-L1+ triple negative breast cancer using the PD-L1 SP142 companion assay

Author

Carter, Jodi M, primary, Polley, Mei-Yin C, additional, Sinnwell, Jason P, additional, Leon-Ferre, Roberto A, additional, Couch, Fergus J, additional, Kalari, Krishna R, additional, Boughey, Judy C, additional, Liu, Minetta C, additional, Visscher, Daniel W, additional, and Goetz, Matthew P, additional

Published
2020
Full Text
View/download PDF

32. Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial

Author

Muss, Hyman B., primary, Polley, Mei-Yin C., additional, Berry, Donald A., additional, Liu, Heshan, additional, Cirrincione, Constance T., additional, Theodoulou, Maria, additional, Mauer, Ann M., additional, Kornblith, Alice B., additional, Partridge, Ann H., additional, Dressler, Lynn G., additional, Cohen, Harvey J., additional, Kartcheske, Patricia A., additional, Perez, Edith A., additional, Wolff, Antonio C., additional, Gralow, Julie R., additional, Burstein, Harold J., additional, Mahmood, Ahmad A., additional, Sutton, Linda M., additional, Magrinat, Gustav, additional, Parker, Barbara A., additional, Hart, Ronald D., additional, Grenier, Debjani, additional, Hurria, Arti, additional, Jatoi, Aminah, additional, Norton, Larry, additional, Hudis, Clifford A., additional, Winer, Eric P., additional, and Carey, Lisa, additional

Published
2019
Full Text
View/download PDF

33. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

Author

Bartlett, Nancy L., primary, Wilson, Wyndham H., additional, Jung, Sin-Ho, additional, Hsi, Eric D., additional, Maurer, Matthew J., additional, Pederson, Levi D., additional, Polley, Mei-Yin C., additional, Pitcher, Brandelyn N., additional, Cheson, Bruce D., additional, Kahl, Brad S., additional, Friedberg, Jonathan W., additional, Staudt, Louis M., additional, Wagner-Johnston, Nina D., additional, Blum, Kristie A., additional, Abramson, Jeremy S., additional, Reddy, Nishitha M., additional, Winter, Jane N., additional, Chang, Julie E., additional, Gopal, Ajay K., additional, Chadburn, Amy, additional, Mathew, Susan, additional, Fisher, Richard I., additional, Richards, Kristy L., additional, Schöder, Heiko, additional, Zelenetz, Andrew D., additional, and Leonard, John P., additional

Published
2019
Full Text
View/download PDF

40. Criteria for use of omics-based predictors in NCI-sponsored clinical trials.

Author

McShane, Lisa A., primary, Conley, Barbara A., additional, Cavenagh, Margaret M., additional, Lively, Tracy G., additional, Eberhard, David A., additional, Williams, Paul M., additional, Bigbee, William L., additional, Mesirov, Jill P., additional, Polley, Mei-Yin C., additional, Kim, Kelly Y., additional, and Tricoli, James V., additional

Published
2012
Full Text
View/download PDF

43. Impact of bevacizumab chemotherapy on craniotomy wound healing

Author

Clark, Aaron J., primary, Butowski, Nicholas A., additional, Chang, Susan M., additional, Prados, Michael D., additional, Clarke, Jennifer, additional, Polley, Mei-Yin C., additional, Sughrue, Michael E., additional, McDermott, Michael W., additional, Parsa, Andrew T., additional, Berger, Mitchel S., additional, and Aghi, Manish K., additional

Published
2011
Full Text
View/download PDF

45. Oncogenic BRAF Mutation with CDKN2A Inactivation Is Characteristic of a Subset of Pediatric Malignant Astrocytomas

Author

Schiffman, Joshua D., primary, Hodgson, J. Graeme, additional, VandenBerg, Scott R., additional, Flaherty, Patrick, additional, Polley, Mei-Yin C., additional, Yu, Mamie, additional, Fisher, Paul G., additional, Rowitch, David H., additional, Ford, James M., additional, Berger, Mitchel S., additional, Ji, Hanlee, additional, Gutmann, David H., additional, and James, C. David, additional

Published
2010
Full Text
View/download PDF

49. Mass Cytometry Analysis Reveals that Specific Intratumoral CD4+T Cell Subsets Correlate with Patient Survival in Follicular Lymphoma

Author

Yang, Zhi-Zhang, Kim, Hyo Jin, Villasboas, Jose C., Price-Troska, Tammy, Jalali, Shahrzad, Wu, Hongyan, Luchtel, Rebecca A., Polley, Mei-Yin C., Novak, Anne J., and Ansell, Stephen M.

Abstract

Follicular lymphoma (FL) is an indolent B cell malignancy characterized by an extensive but poorly functional T cell infiltrate in the tumor microenvironment. Using mass cytometry, we identified at least 12 subsets of intratumoral CD4+T cells, 3 of which were unique to FL biopsies versus control tissues. Of these subsets, the frequency of naive T cells correlated with improved patient survival. Although total PD-1+T cell numbers were not associated with patient outcome, specific PD-1+T cell subpopulations were associated with poor survival. Intratumoral T cells lacking CD27 and CD28 co-stimulatory receptor expression were enriched in FL and correlated with inferior patient outcomes. In vitromodels revealed that CD70+lymphoma cells played an important role in expanding this population. Taken together, our mass cytometry results identified CD4+memory T cell populations that are poorly functional due to loss of co-stimulatory receptor expression and are associated with an inferior survival in FL.

Published
2019
Full Text
View/download PDF

50. Mass Cytometry Analysis Reveals that Specific Intratumoral CD4 + T Cell Subsets Correlate with Patient Survival in Follicular Lymphoma.

Author

Yang ZZ, Kim HJ, Villasboas JC, Price-Troska T, Jalali S, Wu H, Luchtel RA, Polley MC, Novak AJ, and Ansell SM

Subjects
Adult, Aged, Aged, 80 and over, CD28 Antigens genetics, CD28 Antigens metabolism, CD4-Positive T-Lymphocytes classification, Cell Line, Tumor, Cells, Cultured, Female, Humans, Lymphoma, Follicular blood, Lymphoma, Follicular pathology, Male, Middle Aged, Programmed Cell Death 1 Receptor genetics, Programmed Cell Death 1 Receptor metabolism, Tumor Necrosis Factor Receptor Superfamily, Member 7 genetics, Tumor Necrosis Factor Receptor Superfamily, Member 7 metabolism, Biomarkers, Tumor blood, CD4-Positive T-Lymphocytes metabolism, Lymphoma, Follicular immunology, Lymphoma, Follicular mortality, Tumor Microenvironment
Abstract

Follicular lymphoma (FL) is an indolent B cell malignancy characterized by an extensive but poorly functional T cell infiltrate in the tumor microenvironment. Using mass cytometry, we identified at least 12 subsets of intratumoral CD4 + T cells, 3 of which were unique to FL biopsies versus control tissues. Of these subsets, the frequency of naive T cells correlated with improved patient survival. Although total PD-1 + T cell numbers were not associated with patient outcome, specific PD-1 + T cell subpopulations were associated with poor survival. Intratumoral T cells lacking CD27 and CD28 co-stimulatory receptor expression were enriched in FL and correlated with inferior patient outcomes. In vitro models revealed that CD70 + lymphoma cells played an important role in expanding this population. Taken together, our mass cytometry results identified CD4 + memory T cell populations that are poorly functional due to loss of co-stimulatory receptor expression and are associated with an inferior survival in FL., (Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results